doctor checking the manufacturing of the medicines
Hymovis

Content prepared by Direct Doctor Supply’s Editorial team.


Last Updated On September 25, 2026

Hymovis FDA Approval Status

Nov 20, 2024

The knee is a complex joint composed of bones, cartilage, ligaments, and tendons that work together to support movement and bear weight. Osteoarthritis, a condition affecting over 595 million people globally, most commonly impacts the knee joint.

Hymovis, a hyaluronic acid-based viscosupplement, recently received FDA approval to treat knee osteoarthritis pain in patients who have not responded to conservative treatments. This approval highlights Hymovis’s safety and effectiveness, as it has met the FDA’s rigorous standards for therapeutic products.

This article explores the Hymovis FDA approval status, examining the treatment’s safety, efficacy, and its journey toward FDA approval in the United States.

Key Takeaways

  • The FDA has approved Hymovis for treating knee osteoarthritis, highlighting its safety and efficacy as a viscosupplement therapy.
  • Clinical trials demonstrated significant improvements in pain relief, knee function, and quality of life with minimal side effects.
  • Hymovis’s unique hyaluronic acid formulation provides longer-lasting symptom relief than other viscosupplements.
  • Ideal for patients who have not responded to conservative treatments like analgesics or physical therapy, Hymovis addresses pain and mobility limitations effectively.
HYMOVIS 01
HYMOVIS® (German)

$ 629.00
Add To Cart
–+
NEOPHARMED SUPARTZ ITALIAN 5X2.5ML 01
SUPARTZ® (Italian)

$ 319.00
Add To Cart
–+

About: Trusted by over 2,000+ global clients since 2014, Direct Doctor Supply has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Direct Doctor Supply offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world.

The Clinical Trials Leading to Hymovis FDA Approval

Hymovis, a hyaluronic acid derivative, received FDA approval to treat knee osteoarthritis. The approval was based on clinical trials demonstrating its efficacy and safety. One pivotal study involved patients with symptomatic knee osteoarthritis who received intra-articular injections of Hymovis. 

testing the mixture

The results showed significant improvements in knee function, pain reduction, and overall quality of life, with no severe adverse events reported. These findings supported Hymovis as a viable treatment option for patients who have not responded adequately to conservative therapies. Direct Doctor Supply offers authentic, FDA-approved orthopedic products for clinics, healthcare professionals, and eligible buyers, providing a convenient way to buy Hymovis online.

The Regulatory Process for Hymovis Evaluation by the FDA

The FDA’s regulatory process for evaluating Hymovis involved a thorough review of clinical trial data to ensure its safety and efficacy. Before approval, extensive studies assessed how well Hymovis relieved knee pain and improved joint function in patients with osteoarthritis. 

  • MOKHA Study: This pilot study aimed to identify biological, clinical, or structural biomarkers of intra-articular hyaluronic acid injection efficacy to design a larger placebo-controlled clinical trial. It involved 46 patients with symptomatic knee osteoarthritis who received two treatment cycles of Hymovis injections.
  • Randomized, Double-Blind, Active-Controlled Study: This study compared the effectiveness and safety of a single injection of Hymovis ONE, a sodium hyaluronate formulation, with Monovisc, another sodium hyaluronate formulation, to treat pain from knee osteoarthritis.

These trials showed that the gel injection effectively reduced pain and improved mobility. The FDA required evidence of Hymovis’ benefits over existing treatments and its safety profile. After careful analysis, the FDA approved this treatment on August 28, 2015, marking a significant advancement for patients seeking alternatives to surgery and other pain management options.

Assurance of Hymovis Meeting FDA Standards for Patient Use

Patients can be assured that Hymovis meets the FDA’s rigorous standards for safety and efficacy. The approval process involved extensive clinical trials designed to evaluate its potential benefits and any associated risks. These trials included a diverse group of patients with symptomatic knee osteoarthritis who had not responded adequately to conservative therapies.

machine checking

Hymovis has demonstrated a generally well-tolerated safety profile in clinical studies, with reported adverse effects typically mild and temporary, such as pain or swelling at the injection site. The Hymovis FDA approval status reflects its authorization for specific use in managing pain associated with knee osteoarthritis, based on the available evidence supporting its safety and effectiveness.

2025 Review: What Does the Latest Evidence Say About HA?

A 2025 umbrella review examined 22 systematic reviews and meta-analyses of randomized placebo-controlled trials evaluating intra-articular hyaluronic acid for knee osteoarthritis. Twenty reviews reported statistically significant improvements in pain and/or function, while all five reviews rated as high or moderate quality found significant benefits. However, the researchers noted differences in methodological quality and interpretation across reviews, meaning the overall certainty of evidence remains limited. These findings support the potential symptomatic benefits of HA injections while highlighting the importance of considering evidence quality and individual patient factors when evaluating treatment options.[5]

For patients comparing Hymovis vs Synvisc, consult a healthcare provider to determine which treatment option best suits their specific needs and medical history. Both treatments have shown promise in improving quality of life for patients with knee osteoarthritis, but the choice between them can depend on factors such as individual response to treatment and overall health status.

Indications for Hymovis Use in Osteoarthritis Treatment

Hymovis can treat osteoarthritis patients who have not adequately responded to conservative non-pharmacologic therapy or simple analgesics, such as acetaminophen. It is designed explicitly for intra-articular injection into the knee joint.

marking the injection area

It is contraindicated in patients with known hypersensitivity to hyaluronate preparations or gram-positive bacterial proteins, or with infections or skin diseases at the injection site. Hymovis’s safety and effectiveness have not been established in pregnant women, nursing mothers, or children. Additionally, it should not be used in joints other than the knee or in conjunction with other intra-articular injections.

Benefits of Hymovis in Osteoarthritis Management

The key benefit of Hymovis lies in its unique hyaluronic acid formulation. This can reduce pain and improve joint mobility. Hymovis’s biocompatibility and viscoelastic properties make it a valuable option for individuals seeking relief from the limitations imposed by knee osteoarthritis. Additionally, it offers longer-lasting symptom relief than other viscosupplements, allowing patients to manage daily activities with less discomfort.

Conclusion

Hymovis represents an established viscosupplementation option for managing knee osteoarthritis, offering a non-surgical approach to symptomatic relief. The Hymovis FDA approval status reflects its authorization for specific use in managing pain associated with knee osteoarthritis. Its hyaluronic acid formulation is designed to support joint lubrication and cushioning, which may help improve joint function and mobility. Clinical evidence has evaluated its safety and effectiveness in appropriate patients.

By delivering longer-lasting results with minimal risk, Hymovis stands out among viscosupplements as a reliable, innovative treatment for knee osteoarthritis. For individuals seeking to regain mobility and reduce discomfort, Hymovis offers a safe, effective alternative to invasive procedures.

FAQs

1. What is the FDA approval status of Hymovis?

Hymovis is FDA-approved to treat knee osteoarthritis. It received approval based on its safety, efficacy, and detailed prescribing information.

2. What are the potential side effects of Hymovis?

Common side effects may include swelling or stiffness at the injection site. For a comprehensive list of potential side effects, consult the full prescribing information.

3. What is the primary use of Hymovis?

Hymovis is an injectable treatment designed to relieve pain and improve joint mobility in patients with knee osteoarthritis. It replenishes the hyaluronic acid in the joint, enhancing lubrication and reducing inflammation.

Need help, additional info, or customized deals?

Talk with our sales representative.

Book a Meeting

Citations

[1] Premarket Approval (PMA). FDA.gov, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p150010. Accessed 25 Sept. 2026.

[2] Osteoarthritis of the Knee (Degenerative Arthritis of the Knee). WebMD, 15 Aug. 2008. https://www.webmd.com/osteoarthritis/ostearthritis-of-the-knee-degenerative-arthritis-of-the-knee. Accessed 25 Sept. 2026.

[3] Steinmetz, J. D., G. T. Culbreth, L. M. Haile, et al. “Global, Regional, and National Burden of Osteoarthritis, 1990–2020 and Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021.” The Lancet Rheumatology, vol. 5, no. 9, 2023, pp. e508–22. doi:10.1016/s2665-9913(23)00163-7.

[4] Chung, Andrew. Knee Joint Anatomy: Bones, Ligaments, Muscles, Tendons, Function. Healthpages.org, 2010.

[5] Bruyère, Olivier, et al. “Effects of Intra-Articular Hyaluronic Acid Injections on Pain and Function in Patients with Knee Osteoarthritis: An Umbrella Review of Systematic Reviews and Meta-Analyses of Randomized Placebo-Controlled Trials.” Maturitas, vol. 203, Elsevier BV, Nov. 2025, pp. 108779–79. doi:10.1016/j.maturitas.2025.108779.

Sourcing and accuracy for this article follow our Editorial policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published